• News
  • SAN DIEGO
  • BioTech

JPMorgan recommends Acadia

The JPMorgan investment bank initiated coverage of Acadia Pharmaceuticals (Nasdaq: ACAD) on Thursday with a target price of $33, far above its current price in the $19 range.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Acadia Pharmaceuticals Inc.

Company Website

3911 Sorrento Valley Blvd.
San Diego, CA 92121

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ACAD
26.64
  -0.93  
- 3.37%
1,948,886,000
32.00
15.64

Insider Trade Data

Date Insider Shares Type Value
09/15/2014 Brege, Laura A 10,000 Exchange $17,500
09/15/2014 Brege, Laura A 10,000 Sell $280,669
09/12/2014 Wells, William Mcdowall 9,190 Sell $267,873
09/12/2014 Wells, William Mcdowall 9,190 Exchange $12,498
09/10/2014 Hacksell, Uli 30,000 Exchange $60,000

Acadia Pharmaceuticals Inc. Executive(s):

Uli Hacksell

  • Chief Executive Officer, President

Similar Companies

NAICS - 325412 - Pharmaceutical Preparation Manufacturing
SIC - 2834 - PHARMACEUTICAL PREPARATIONS
SIC - 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES
NAICS - 541711 - Research and Development in Biotechnology
SIC - 8731 - COMMERCIAL PHYSICAL AND BIOLOGICAL RESEARCH
SIC - 8733 - NONCOMMERCIAL RESEARCH ORGANIZATIONS
Subscribe Today!